Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO) saw its stock increase by 7.4% after revealing a new clinical study collaboration with AGEPHA Pharma focused on treating inflammation-driven coronary heart disease.
The partnership will involve using AGEPHA’s FDA-approved low-dose colchicine drug, LODOCO, within a study sponsored by Cardio Diagnostics. The study plans to leverage Cardio’s PrecisionCHD blood test to identify patients whose coronary heart disease is driven by inflammation, prescribing LODOCO when clinically appropriate.
Participants will be retested to monitor changes in inflammation markers by analyzing DNA methylation patterns. The PrecisionCHD test employs artificial intelligence to examine six specific DNA methylation markers linked to modifiable risk factors of coronary heart disease, including inflammation.
“This study reflects a precision medicine model where diagnosis and treatment are both guided by the patient’s unique molecular insights,” stated Robert Philibert, Chief Medical Officer at Cardio Diagnostics.
Currently, Cardio Diagnostics is assessing potential clinical sites for the trial. The final study protocol will be developed alongside the principal investigator at the chosen sites and officially registered as a clinical trial.
This effort supports the American Heart Association’s recent $15 million initiative to explore the role of inflammation in cardiovascular and brain health. The collaboration seeks to validate what the company calls a precision-guided method to managing inflammation-driven coronary heart disease.